nygazet.com logo
OTC nasal spray seemed to cut COVID infections by 67% in mid-sized trial
health

OTC nasal spray seemed to cut COVID infections by 67% in mid-sized trial

1 min read

The Phase 2 trial is not definitive, but it comes as vaccine access is severely restricted.

Daily squirts of a safe, over-the-counter allergy nasal spray may prevent COVID-19 infections from taking hold, according to results published Tuesday in JAMA Internal Medicine. In a mid-staged trial, the spray appeared to reduce infections by promis... [2138 chars]

Read Original Article

Source: Ars Technica

Visit Source

Share this article